BioLineRx Ltd. (BLRX) Announces Positive Final Results for Its Neuropathic Pain Drug
BioLineRx Ltd. is a biopharmaceutical development company dedicated to building a portfolio of products for addressing unmet medical needs or that have advantages over currently available therapies. The company's current product portfolio consists of five clinical stage candidates, including BL-1021, an orally available small molecule for neuropathic pain. The company announced today the final results of the Phase 1a study of BL-1021. In this study, it was demonstrated that a single administration of BL-1021 in the dose range examined was safe and well tolerated. There were no significant changes noted in vital signs, ECG or laboratory safety parameters at any…